I also believe that the reason why Atomo hasn't come to get multiple sizeable contracts is due to their ability to manage the political relationships and negotiate the business deals.
However, having said that, John Kelly has been in the media quite a lot recently, and you would need a good marketing team for that (especially for the media to put a positive spin in the articles).
If Atomo's product is more superior and better quality than its competitors, and if their communications are transparent and with integrity, then I believe (as with anything) that the longer they maintain this composure and the longer they continue to knock on the doors of others, the more likely that in the long term they will win multiple sizeable contracts. As with any starting out business, it's always a grind at the start and there'll always be many many naysayers. However, if you look at the front few pages of Atomo's recent annual report, you'll see that they're not just focused on COVID-19, or HIV (e.g. their vision isn't to be the best in HIV or COVID-19 kits), but rather they are trying to change lives and challenge the current norm. This stems from core values and beliefs and I believe is a far better determinant of long term success.
- Forums
- ASX - By Stock
- AT1
- Media Update
AT1
atomo diagnostics limited
Add to My Watchlist
0.00%
!
1.4¢

Media Update, page-1085
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.31M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 3821439 | 1.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.5¢ | 1397440 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 3636439 | 0.014 |
8 | 1239260 | 0.013 |
5 | 605833 | 0.012 |
3 | 618725 | 0.011 |
6 | 4120000 | 0.010 |
Price($) | Vol. | No. |
---|---|---|
0.015 | 599940 | 3 |
0.016 | 1095924 | 4 |
0.017 | 1289350 | 7 |
0.018 | 686654 | 5 |
0.019 | 156750 | 4 |
Last trade - 16.21pm 04/07/2025 (20 minute delay) ? |
Featured News
AT1 (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online